Hans-Christian Kolberg1, Gyoergy Loevey2, Leyla Akpolat-Basci3, Miltiades Stephanou3, Peter A Fasching4, Michael Untch5, Cornelia Liedtke6, Max Bulsara7,8, Jayant S Vaidya8. 1. Department of Gynecology and Obstetrics, Marienhospital Bottrop gGmbH, Josef-Albers-Str. 70, 46236, Bottrop, Germany. hans-christian.kolberg@mhb-bottrop.de. 2. BORAD, Bottrop, Germany. 3. Department of Gynecology and Obstetrics, Marienhospital Bottrop gGmbH, Josef-Albers-Str. 70, 46236, Bottrop, Germany. 4. University of Erlangen, Erlangen, Germany. 5. Helios Klinikum Berlin-Buch, Berlin, Germany. 6. University Hospital Schleswig-Holstein/Campus Lübeck, Lübeck, Germany. 7. University of Notre Dame, Fremantle, Australia. 8. University College, London, UK.
Abstract
INTRODUCTION: The use of targeted intraoperative radiotherapy (TARGIT-IORT) as a tumour bed boost during breast-conserving surgery (BCS) for breast cancer has been reported since 1998. We present its use in patients undergoing breast conservation following neoadjuvant therapy (NACT). METHOD: In this retrospective study involving 116 patients after NACT we compared outcomes of 61 patients who received a tumour bed boost with IORT during lumpectomy versus 55 patients treated in the previous 13 months with external (EBRT) boost. All patients received whole breast radiotherapy. Local recurrence-free survival (LRFS), disease-free survival (DFS), distant disease-free survival (DDFS), breast cancer mortality (BCM), non-breast cancer mortality (NBCM) and overall mortality (OS) were compared. RESULTS: Median follow up was 49 months. The differences in LRFS, DFS and BCM were not statistically significant. The 5‑year Kaplan-Meier estimate of OS was significantly better by 15% with IORT: IORT 2 events (96.7%, 95%CI 87.5-99.2), EBRT 9 events (81.7%, 95%CI 67.6-90.1), hazard ratio (HR) 0.19 (0.04-0.87), log rank p = 0.016, mainly due to a reduction of 10.1% in NBCM: IORT 100%, EBRT 89.9% (77.3-95.7), HR (not calculable), log rank p = 0.015. The DDFS was as follows: IORT 3 events (95.1%, 85.5-98.4), EBRT 12 events (69.0%, 49.1-82.4), HR 0.23 (0.06-0.80), log rank p = 0.012. CONCLUSION: IORT during lumpectomy after neoadjuvant chemotherapy as a tumour bed boost appears to give results that are not worse than external beam radiotherapy boost. These data give further support to the inclusion of such patients in the TARGIT-B (boost) randomised trial that is testing whether IORT boost is superior to EBRT boost.
INTRODUCTION: The use of targeted intraoperative radiotherapy (TARGIT-IORT) as a tumour bed boost during breast-conserving surgery (BCS) for breast cancer has been reported since 1998. We present its use in patients undergoing breast conservation following neoadjuvant therapy (NACT). METHOD: In this retrospective study involving 116 patients after NACT we compared outcomes of 61 patients who received a tumour bed boost with IORT during lumpectomy versus 55 patients treated in the previous 13 months with external (EBRT) boost. All patients received whole breast radiotherapy. Local recurrence-free survival (LRFS), disease-free survival (DFS), distant disease-free survival (DDFS), breast cancer mortality (BCM), non-breast cancer mortality (NBCM) and overall mortality (OS) were compared. RESULTS: Median follow up was 49 months. The differences in LRFS, DFS and BCM were not statistically significant. The 5‑year Kaplan-Meier estimate of OS was significantly better by 15% with IORT: IORT 2 events (96.7%, 95%CI 87.5-99.2), EBRT 9 events (81.7%, 95%CI 67.6-90.1), hazard ratio (HR) 0.19 (0.04-0.87), log rank p = 0.016, mainly due to a reduction of 10.1% in NBCM: IORT 100%, EBRT 89.9% (77.3-95.7), HR (not calculable), log rank p = 0.015. The DDFS was as follows: IORT 3 events (95.1%, 85.5-98.4), EBRT 12 events (69.0%, 49.1-82.4), HR 0.23 (0.06-0.80), log rank p = 0.012. CONCLUSION: IORT during lumpectomy after neoadjuvant chemotherapy as a tumour bed boost appears to give results that are not worse than external beam radiotherapy boost. These data give further support to the inclusion of such patients in the TARGIT-B (boost) randomised trial that is testing whether IORT boost is superior to EBRT boost.
Entities:
Keywords:
Breast cancer; External boost; Intraoperative radiotherapy; Neoadjuvant therapy; Tumor bed boost
Authors: Gerd Fastner; Roland Reitsamer; Ingrid Ziegler; Franz Zehentmayr; Christoph Fussl; Peter Kopp; Florentia Peintinger; Richard Greil; Thorsten Fischer; Heinrich Deutschmann; Felix Sedlmayer Journal: Int J Cancer Date: 2014-07-10 Impact factor: 7.396
Authors: Jens Huober; Gunter von Minckwitz; Carsten Denkert; Hans Tesch; Erich Weiss; Dirk Michael Zahm; Antje Belau; Fariba Khandan; Maik Hauschild; Christoph Thomssen; Bernhard Högel; Silvia Darb-Esfahani; Keyur Mehta; Sibylle Loibl Journal: Breast Cancer Res Treat Date: 2010-08-10 Impact factor: 4.872
Authors: Jayant S Vaidya; Michael Baum; Jeffrey S Tobias; Frederik Wenz; Samuele Massarut; Mohammed Keshtgar; Basil Hilaris; Christobel Saunders; Norman R Williams; Chris Brew-Graves; Tammy Corica; Mario Roncadin; Uta Kraus-Tiefenbacher; Marc Sütterlin; Max Bulsara; David Joseph Journal: Int J Radiat Oncol Biol Phys Date: 2010-10-15 Impact factor: 7.038
Authors: Gerd Fastner; Cornelia Hauser-Kronberger; Angelika Moder; Roland Reitsamer; Franz Zehentmayr; Peter Kopp; Christoph Fussl; Thorsten Fischer; Heinrich Deutschmann; Felix Sedlmayer Journal: Strahlenther Onkol Date: 2015-09-24 Impact factor: 3.621
Authors: Barbara Belletti; Jayant S Vaidya; Sara D'Andrea; Frank Entschladen; Mario Roncadin; Francesca Lovat; Stefania Berton; Tiziana Perin; Ezio Candiani; Sonia Reccanello; Andrea Veronesi; Vincenzo Canzonieri; Mauro G Trovò; Kurt S Zaenker; Alfonso Colombatti; Gustavo Baldassarre; Samuele Massarut Journal: Clin Cancer Res Date: 2008-03-01 Impact factor: 12.531
Authors: Naomi S Sta Maria; Samuel R Barnes; Michael R Weist; David Colcher; Andrew A Raubitschek; Russell E Jacobs Journal: PLoS One Date: 2015-11-10 Impact factor: 3.240
Authors: Jayant S Vaidya; Frederik Wenz; Max Bulsara; Jeffrey S Tobias; David J Joseph; Mohammed Keshtgar; Henrik L Flyger; Samuele Massarut; Michael Alvarado; Christobel Saunders; Wolfgang Eiermann; Marinos Metaxas; Elena Sperk; Marc Sütterlin; Douglas Brown; Laura Esserman; Mario Roncadin; Alastair Thompson; John A Dewar; Helle M R Holtveg; Steffi Pigorsch; Mary Falzon; Eleanor Harris; April Matthews; Chris Brew-Graves; Ingrid Potyka; Tammy Corica; Norman R Williams; Michael Baum Journal: Lancet Date: 2013-11-11 Impact factor: 79.321
Authors: Hans-Christian Kolberg; György Lövey; Leyla Akpolat-Basci; Miltiades Stephanou; Peter Fasching; Michael Untch; Oliver Hoffmann; Max Bulsara; Jayant Vaidya; Cornelia Liedtke Journal: Breast Care (Basel) Date: 2017-09-21 Impact factor: 2.860
Authors: Jayant S Vaidya; Max Bulsara; Michael Baum; Frederik Wenz; Samuele Massarut; Steffi Pigorsch; Michael Alvarado; Michael Douek; Christobel Saunders; Henrik Flyger; Wolfgang Eiermann; Chris Brew-Graves; Norman R Williams; Ingrid Potyka; Nicholas Roberts; Marcelle Bernstein; Douglas Brown; Elena Sperk; Siobhan Laws; Marc Sütterlin; Tammy Corica; Steinar Lundgren; Dennis Holmes; Lorenzo Vinante; Fernando Bozza; Montserrat Pazos; Magali Le Blanc-Onfroy; Günther Gruber; Wojciech Polkowski; Konstantin J Dedes; Marcus Niewald; Jens Blohmer; David McReady; Richard Hoefer; Pond Kelemen; Gloria Petralia; Mary Falzon; David Joseph; Jeffrey S Tobias Journal: Br J Cancer Date: 2021-05-25 Impact factor: 7.640